NO324219B1 - Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom - Google Patents

Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom

Info

Publication number
NO324219B1
NO324219B1 NO20030097A NO20030097A NO324219B1 NO 324219 B1 NO324219 B1 NO 324219B1 NO 20030097 A NO20030097 A NO 20030097A NO 20030097 A NO20030097 A NO 20030097A NO 324219 B1 NO324219 B1 NO 324219B1
Authority
NO
Norway
Prior art keywords
group
treatment
medicaments
drugs
disease
Prior art date
Application number
NO20030097A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030097L (no
NO20030097D0 (no
Inventor
Hiromichi Shigyo
Masao Ohkuchi
Yoshinori Kyotani
Tomoyuki Koshi
Tadaaki Ohgiya
Takayuki Matsuda
Natsuyo Kumai
Kyoko Yasuoka
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of NO20030097L publication Critical patent/NO20030097L/no
Publication of NO20030097D0 publication Critical patent/NO20030097D0/no
Publication of NO324219B1 publication Critical patent/NO324219B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20030097A 2000-07-10 2003-01-09 Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom NO324219B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/612,953 US6664256B1 (en) 2000-07-10 2000-07-10 Phenylpyridazine compounds and medicines containing the same
PCT/JP2001/005904 WO2002004427A1 (fr) 2000-07-10 2001-07-06 Derives de phenylpyridazine et medicaments contenant ces derniers

Publications (3)

Publication Number Publication Date
NO20030097L NO20030097L (no) 2003-01-09
NO20030097D0 NO20030097D0 (no) 2003-01-09
NO324219B1 true NO324219B1 (no) 2007-09-10

Family

ID=24455274

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030097A NO324219B1 (no) 2000-07-10 2003-01-09 Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom

Country Status (15)

Country Link
US (1) US6664256B1 (fr)
EP (1) EP1300399B1 (fr)
JP (1) JP4915715B2 (fr)
KR (1) KR100777623B1 (fr)
CN (1) CN1272326C (fr)
AT (1) ATE370735T1 (fr)
AU (2) AU6947401A (fr)
CA (1) CA2413042A1 (fr)
DE (1) DE60130119T2 (fr)
HU (1) HUP0301230A3 (fr)
NO (1) NO324219B1 (fr)
NZ (1) NZ523242A (fr)
RU (1) RU2269519C2 (fr)
TW (1) TW593285B (fr)
WO (1) WO2002004427A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9813998A (pt) * 1997-11-19 2000-09-26 Kowa Co Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos
US6869954B2 (en) * 2001-09-26 2005-03-22 Kowa Co., Ltd. Water-soluble phenylpyridazine compounds and compositions containing the same
AU2003247425B2 (en) * 2002-05-22 2007-03-08 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
EP2270006A1 (fr) 2002-08-08 2011-01-05 Amgen, Inc Dérivés de pyridazine en tant que ligands de récepteur vanilloïde
EP1688408A3 (fr) * 2002-08-08 2007-08-22 Amgen, Inc Ligands du récepteur vanilloide et leur utilisation dans des traitements
NZ541064A (en) * 2003-03-07 2007-09-28 Kowa Co Benzofuran derivative
AU2004221966A1 (en) * 2003-03-18 2004-09-30 Kowa Co., Ltd. Water-soluble phenylpyridazine derivative and medicine containing the same
EP1650195A4 (fr) * 2003-07-30 2008-09-17 Kowa Co Methode servant a inhiber la production d'osteopontine
PL1668105T3 (pl) 2003-09-29 2019-03-29 Deb Ip Limited Kompozycje żelopodobne i pieniące o dużej zawartości alkoholu
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
DE102004062775A1 (de) 2004-12-21 2006-06-29 Stockhausen Gmbh Alkoholischer Pumpschaum
KR101512843B1 (ko) 2005-03-07 2015-04-16 디이비 월드와이드 헬스케어 인코포레이티드 실리콘-기제 계면활성제를 갖는 고함량 알코올 폼 형성조성물
WO2006113704A2 (fr) * 2005-04-18 2006-10-26 Neurogen Corporation Antagonistes cb1 heteroaryle substitue
WO2007123939A2 (fr) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Nouveaux arylamino n-hétéraryles en tant qu'inhibiteurs de mek
US8580860B2 (en) * 2007-02-23 2013-11-12 Gojo Industries, Inc. Foamable alcoholic composition
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
EP2429295B1 (fr) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
GB2497476B (en) 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
WO2012111024A1 (fr) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Compositions pharmaceutiques de dexlansoprazole
WO2021193897A1 (fr) * 2020-03-27 2021-09-30 アステラス製薬株式会社 Composé de pyridazine substitué

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840597A (en) 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
US4092311A (en) * 1976-06-03 1978-05-30 American Cyanamid Company Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
FI91062C (fi) 1988-12-28 1994-05-10 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisten naftaleenijohdannaisten valmistamiseksi
WO1992002513A1 (fr) * 1990-08-06 1992-02-20 Fujisawa Pharmaceutical Co., Ltd. Composes heterocycliques
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
DK0628550T3 (da) 1993-06-08 1998-09-28 Vertex Pharma Pyridazin som interleukin-1 beta-omdannede enzyminhibitorer
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
WO1997005878A1 (fr) 1995-08-10 1997-02-20 Merck & Co., Inc. Pyrroles d'aryle substitues en position 2 et 5, compositions contenant de tels composes et leurs modes d'utilisation
WO1998041511A1 (fr) 1997-03-14 1998-09-24 Merck Frosst Canada & Co. Pyridazinones utilises comme inhibiteurs de cyclo-oxygenase-2
WO1999010332A1 (fr) 1997-08-22 1999-03-04 Abbott Laboratories Inhibiteurs de la biosynthese de la prostaglandine h2 synthetase
CA2299300C (fr) 1997-08-22 2007-04-17 Abbott Laboratories Arylpyridazinones inhibitrices de la biosynthese de la prostaglandine endoperoxyde h synthase
BR9813998A (pt) 1997-11-19 2000-09-26 Kowa Co Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos
JP3999861B2 (ja) * 1997-11-19 2007-10-31 興和株式会社 新規ピリダジン誘導体及びこれを有効成分とする医薬
HUP0101099A3 (en) * 1997-12-19 2002-09-30 Amgen Inc Thousand Oaks Substituted pyridine and pyridazine compounds and their pharmaceutical use
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
CN1279026C (zh) 1998-10-27 2006-10-11 艾博特公司 前列腺素内过氧化物h合酶生物合成抑制剂
US6350744B1 (en) * 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity

Also Published As

Publication number Publication date
AU6947401A (en) 2002-01-21
HUP0301230A2 (hu) 2003-12-29
HUP0301230A3 (en) 2004-03-29
EP1300399A1 (fr) 2003-04-09
KR20030007948A (ko) 2003-01-23
CN1440392A (zh) 2003-09-03
AU2001269474B2 (en) 2005-09-15
DE60130119T2 (de) 2007-12-13
EP1300399A4 (fr) 2004-02-11
KR100777623B1 (ko) 2007-11-27
CN1272326C (zh) 2006-08-30
US6664256B1 (en) 2003-12-16
NO20030097L (no) 2003-01-09
JP4915715B2 (ja) 2012-04-11
DE60130119D1 (de) 2007-10-04
TW593285B (en) 2004-06-21
EP1300399B1 (fr) 2007-08-22
RU2269519C2 (ru) 2006-02-10
CA2413042A1 (fr) 2002-01-17
NZ523242A (en) 2004-10-29
WO2002004427A1 (fr) 2002-01-17
ATE370735T1 (de) 2007-09-15
NO20030097D0 (no) 2003-01-09

Similar Documents

Publication Publication Date Title
NO324219B1 (no) Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom
DE69829875D1 (de) Piperazin-verbindungen und ihre medizinische verwendung
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
DK1213296T3 (da) Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
HUP0302167A2 (hu) Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
DE69426331D1 (de) Arzneimittel gegen nervöse erkrankungen
MY145408A (en) Dihydropyrazolopyrimidinone derivatives
MXPA04001507A (es) Derivado de tetrazoiloxima y producto quimico agricola que contiene el mismo como ingrediente activo.
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
EP1702917A4 (fr) Derive d'amide et medicament
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
DE3869907D1 (de) Chinolincarbonsaeure-derivate.
WO2000068198A3 (fr) Derives de pyridine heterosubstitues utilises comme inhibiteurs de pde 4
WO2000064874A3 (fr) DERIVES DE PYRIDINE HETEROSUBSTITUES INHIBITEURS DE $i(PDE 4)
EP1142881A4 (fr) Inhibiteurs de poly(adp-ribose) polymerase consistant en des derives de pyrimidine
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
NO20014099D0 (no) Pyridazin-3-on derivater og medikamenter inneholdende disse
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung
BR0308935A (pt) Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
PT1140925E (pt) 3,4-di-hidro-2h-benzo¬1,4|oxazinil-metil-¬3-(1h-indol-3il)-alquil|-aminas
HUP0204579A2 (hu) Pirrolopiridazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20063353L (no) 1,2,3,4-tetrahydroisokinolinderivater, fremgangsmate for fremstilling derav og anvendelser derav
IT1247137B (it) Derivati dell'acido 5-fenil-1h-pirazol-4-propionico, loro preparazione e loro impiego come medicamenti

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees